organization · Reporting owner
PHOENIX BIOTECH SPONSOR, LLC
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CERO THERAPEUTICS HOLDINGS, INC.CERO · Entity 8622 | 10% owner | February 14, 2024 | February 17, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CERO THERAPEUTICS HOLDINGS, INC.
Report date February 14, 2024 · Filed February 17, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,171,246 |
Reported balance
After 2024-02-14 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2024-02-14 · Other · Disposed 1,125,000 · Balance 4,171,246 F4: Represents shares of Common Stock forfeited to the Issuer for no consideration in connection with the Issuer's initial business combination. |
| Common StockSEC Table I · non-derivative | Direct | 1,000,000 |
Reported balance
After 2024-02-14 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2024-02-14 · Other · Disposed 4,171,246 · Balance 1,000,000 F1: Represents shares of Common Stock, Series A Preferred Stock or warrants, as applicable, distributed-in-kind by the reporting person to its members, pro rata and without consideration. |
| Convertible Promissory NoteSEC Table II · derivative / convertible security · Conversion / exercise price $10.00 | Direct | 0 |
Reported balance
After 2024-02-14 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-02-14 · Exercise / conversion · Disposed 0 · Balance 0 F2: Upon closing of the Issuer's initial business combination, the aggregate principal amount of the Convertible Promissory Note converted into shares of Series A Convertible Preferred Stock (the "Series A Preferred Stock") at a conversion price equal to $10.00. |
| Series A Convertible Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $10.00 | Direct | 1,555 |
Reported balance
After 2024-02-14 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-02-14 · Exercise / conversion · Acquired 1,555 · Balance 1,555 F2: Upon closing of the Issuer's initial business combination, the aggregate principal amount of the Convertible Promissory Note converted into shares of Series A Convertible Preferred Stock (the "Series A Preferred Stock") at a conversion price equal to $10.00. F3: Each share of Series A Preferred Stock has a stated value of $1,000 and, at the option of the holder, is convertible into a number of shares of Common Stock determined by dividing (x) the value of the shares of Series A Preferred Stock, plus any additional amounts thereon as of such date of determination, by (y) the conversion price, which is currently $10.00, subject to adjustments. The Series A Preferred Stock has no expiration date. |
| Series A Convertible Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $10.00 | Direct | 0 |
Reported balance
After 2024-02-14 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-02-14 · Other · Disposed 1,555 · Balance 0 F1: Represents shares of Common Stock, Series A Preferred Stock or warrants, as applicable, distributed-in-kind by the reporting person to its members, pro rata and without consideration. F3: Each share of Series A Preferred Stock has a stated value of $1,000 and, at the option of the holder, is convertible into a number of shares of Common Stock determined by dividing (x) the value of the shares of Series A Preferred Stock, plus any additional amounts thereon as of such date of determination, by (y) the conversion price, which is currently $10.00, subject to adjustments. The Series A Preferred Stock has no expiration date. |
| WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $11.50 · Expires 2029-02-14 | Direct | 0 |
Reported balance
After 2024-02-14 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2024-02-14 · Other · Disposed 349,998 · Balance 0 F1: Represents shares of Common Stock, Series A Preferred Stock or warrants, as applicable, distributed-in-kind by the reporting person to its members, pro rata and without consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of Common Stock, Series A Preferred Stock or warrants, as applicable, distributed-in-kind by the reporting person to its members, pro rata and without consideration.
F2: Upon closing of the Issuer's initial business combination, the aggregate principal amount of the Convertible Promissory Note converted into shares of Series A Convertible Preferred Stock (the "Series A Preferred Stock") at a conversion price equal to $10.00.
F3: Each share of Series A Preferred Stock has a stated value of $1,000 and, at the option of the holder, is convertible into a number of shares of Common Stock determined by dividing (x) the value of the shares of Series A Preferred Stock, plus any additional amounts thereon as of such date of determination, by (y) the conversion price, which is currently $10.00, subject to adjustments. The Series A Preferred Stock has no expiration date.
F4: Represents shares of Common Stock forfeited to the Issuer for no consideration in connection with the Issuer's initial business combination.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 14, 2024 Filed Feb 17, 2024 00:38 UTC | CERO THERAPEUTICS HOLDINGS, INC. CERO · Entity 8622 | OtherWarrants · Derivative | 349,998 | $0.00 Strike: $11.50 | $0.00 |
DisclosureSEC source: 0001213900-24-015028 · ownership.xml · derivative · entry 6 PHOENIX BIOTECH SPONSOR, LLC · CIK 0001870407 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 349,998 shares Expires 2029-02-14 F1 · kind: Represents shares of Common Stock, Series A Preferred Stock or warrants, as applicable, distributed-in-kind by the reporting person to its members, pro rata and without consideration. Read SEC document |
| February 14, 2024 Filed Feb 17, 2024 00:38 UTC | CERO THERAPEUTICS HOLDINGS, INC. CERO · Entity 8622 | OtherSeries A Convertible Preferred Stock · Derivative | 1,555 | $1,000.00 Strike: $10.00 | $1,555,000.00 |
DisclosureSEC source: 0001213900-24-015028 · ownership.xml · derivative · entry 5 PHOENIX BIOTECH SPONSOR, LLC · CIK 0001870407 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 155,500 shares Expires not disclosed F1 · kind: Represents shares of Common Stock, Series A Preferred Stock or warrants, as applicable, distributed-in-kind by the reporting person to its members, pro rata and without consideration. F3 · derivative.exercise_date: Each share of Series A Preferred Stock has a stated value of $1,000 and, at the option of the holder, is convertible into a number of shares of Common Stock determined by dividing (x) the value of the shares of Series A Preferred Stock, plus any additional amounts thereon as of such date of determination, by (y) the conversion price, which is currently $10.00, subject to adjustments. The Series A Preferred Stock has no expiration date. F3 · derivative.expiration_date: Each share of Series A Preferred Stock has a stated value of $1,000 and, at the option of the holder, is convertible into a number of shares of Common Stock determined by dividing (x) the value of the shares of Series A Preferred Stock, plus any additional amounts thereon as of such date of determination, by (y) the conversion price, which is currently $10.00, subject to adjustments. The Series A Preferred Stock has no expiration date. Read SEC document |
| February 14, 2024 Filed Feb 17, 2024 00:38 UTC | CERO THERAPEUTICS HOLDINGS, INC. CERO · Entity 8622 | Exercise / conversionSeries A Convertible Preferred Stock · Derivative | 1,555 | $1,000.00 Strike: $10.00 | $1,555,000.00 |
DisclosureSEC source: 0001213900-24-015028 · ownership.xml · derivative · entry 4 PHOENIX BIOTECH SPONSOR, LLC · CIK 0001870407 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,555 Underlying: Common Stock · 155,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Upon closing of the Issuer's initial business combination, the aggregate principal amount of the Convertible Promissory Note converted into shares of Series A Convertible Preferred Stock (the "Series A Preferred Stock") at a conversion price equal to $10.00. F3 · derivative.exercise_date: Each share of Series A Preferred Stock has a stated value of $1,000 and, at the option of the holder, is convertible into a number of shares of Common Stock determined by dividing (x) the value of the shares of Series A Preferred Stock, plus any additional amounts thereon as of such date of determination, by (y) the conversion price, which is currently $10.00, subject to adjustments. The Series A Preferred Stock has no expiration date. F3 · derivative.expiration_date: Each share of Series A Preferred Stock has a stated value of $1,000 and, at the option of the holder, is convertible into a number of shares of Common Stock determined by dividing (x) the value of the shares of Series A Preferred Stock, plus any additional amounts thereon as of such date of determination, by (y) the conversion price, which is currently $10.00, subject to adjustments. The Series A Preferred Stock has no expiration date. Read SEC document |
| February 14, 2024 Filed Feb 17, 2024 00:38 UTC | CERO THERAPEUTICS HOLDINGS, INC. CERO · Entity 8622 | Exercise / conversionConvertible Promissory Note · Derivative | 0 | $0.00 Strike: $10.00 | $0.00 |
DisclosureSEC source: 0001213900-24-015028 · ownership.xml · derivative · entry 3 PHOENIX BIOTECH SPONSOR, LLC · CIK 0001870407 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · Not disclosed shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Upon closing of the Issuer's initial business combination, the aggregate principal amount of the Convertible Promissory Note converted into shares of Series A Convertible Preferred Stock (the "Series A Preferred Stock") at a conversion price equal to $10.00. F2 · shares: Upon closing of the Issuer's initial business combination, the aggregate principal amount of the Convertible Promissory Note converted into shares of Series A Convertible Preferred Stock (the "Series A Preferred Stock") at a conversion price equal to $10.00. F2 · derivative.exercise_date: Upon closing of the Issuer's initial business combination, the aggregate principal amount of the Convertible Promissory Note converted into shares of Series A Convertible Preferred Stock (the "Series A Preferred Stock") at a conversion price equal to $10.00. F2 · derivative.expiration_date: Upon closing of the Issuer's initial business combination, the aggregate principal amount of the Convertible Promissory Note converted into shares of Series A Convertible Preferred Stock (the "Series A Preferred Stock") at a conversion price equal to $10.00. F2 · derivative.underlying_shares: Upon closing of the Issuer's initial business combination, the aggregate principal amount of the Convertible Promissory Note converted into shares of Series A Convertible Preferred Stock (the "Series A Preferred Stock") at a conversion price equal to $10.00. Read SEC document |
| February 14, 2024 Filed Feb 17, 2024 00:38 UTC | CERO THERAPEUTICS HOLDINGS, INC. CERO · Entity 8622 | OtherCommon Stock | 4,171,246 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-24-015028 · ownership.xml · nonDerivative · entry 2 PHOENIX BIOTECH SPONSOR, LLC · CIK 0001870407 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,000,000 F1 · kind: Represents shares of Common Stock, Series A Preferred Stock or warrants, as applicable, distributed-in-kind by the reporting person to its members, pro rata and without consideration. F1 · price: Represents shares of Common Stock, Series A Preferred Stock or warrants, as applicable, distributed-in-kind by the reporting person to its members, pro rata and without consideration. Read SEC document |
| February 14, 2024 Filed Feb 17, 2024 00:38 UTC | CERO THERAPEUTICS HOLDINGS, INC. CERO · Entity 8622 | OtherCommon Stock | 1,125,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-24-015028 · ownership.xml · nonDerivative · entry 1 PHOENIX BIOTECH SPONSOR, LLC · CIK 0001870407 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,171,246 F4 · kind: Represents shares of Common Stock forfeited to the Issuer for no consideration in connection with the Issuer's initial business combination. F4 · price: Represents shares of Common Stock forfeited to the Issuer for no consideration in connection with the Issuer's initial business combination. Read SEC document |
| October 08, 2021 Filed Oct 12, 2021 23:41 UTC | CERO THERAPEUTICS HOLDINGS, INC. PBAX · Entity 8622 | OtherWarrants · Derivative | 18,366 | $0.00 Strike: $11.50 | $0.00 |
DisclosureSEC source: 0000899243-21-039943 · doc4.xml · derivative · entry 3 PHOENIX BIOTECH SPONSOR, LLC · CIK 0001870407 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 349,998 Underlying: Class A Common Stock · 18,366 shares Expires not disclosed F1 · kind: Acquisition by reporting person in connection with the partial exercise of the underwriters' over-allotment option. F5 · derivative.exercise_date: The warrants will become exercisable at the later of 30 days after the consummation of the issuer's initial business combination or 12 months from the completion of the issuer's initial public offering. F6 · derivative.expiration_date: The warrants will expire five years after the consummation of the issuer's initial business combination or earlier upon redemption of all of the issuer's outstanding Class A common shares or the issuer's liquidation. Read SEC document |
| October 08, 2021 Filed Oct 12, 2021 23:41 UTC | CERO THERAPEUTICS HOLDINGS, INC. PBAX · Entity 8622 | OtherClass B Common Stock · Derivative | 82,875 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-039943 · doc4.xml · derivative · entry 2 PHOENIX BIOTECH SPONSOR, LLC · CIK 0001870407 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,596,250 Underlying: Class A Common Stock · 82,875 shares Expires not disclosed F3 · derivative.exercise_price: The shares of Class B common stock will automatically convert into shares of Class A common stock at the time of the issuer's initial business combination on a one-for-one basis, subject to certain adjustments described in the issuer's charter documents and have no expiration date. F4 · kind: Forfeiture and cancellation of shares of Class B common stock for no consideration because the underwriters' over-allotment option was not exercised in full. F4 · price: Forfeiture and cancellation of shares of Class B common stock for no consideration because the underwriters' over-allotment option was not exercised in full. F3 · derivative.exercise_date: The shares of Class B common stock will automatically convert into shares of Class A common stock at the time of the issuer's initial business combination on a one-for-one basis, subject to certain adjustments described in the issuer's charter documents and have no expiration date. F3 · derivative.expiration_date: The shares of Class B common stock will automatically convert into shares of Class A common stock at the time of the issuer's initial business combination on a one-for-one basis, subject to certain adjustments described in the issuer's charter documents and have no expiration date. Read SEC document |
| October 08, 2021 Filed Oct 12, 2021 23:41 UTC | CERO THERAPEUTICS HOLDINGS, INC. PBAX · Entity 8622 | OtherClass A common stock | 36,733 | $10.00 | $367,330.00 |
DisclosureSEC source: 0000899243-21-039943 · doc4.xml · nonDerivative · entry 1 PHOENIX BIOTECH SPONSOR, LLC · CIK 0001870407 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 699,996 F1 · kind: Acquisition by reporting person in connection with the partial exercise of the underwriters' over-allotment option. F2 · shares: These shares underlie the same number of units of the issuer held by the reporting person. F2 · balance_after: These shares underlie the same number of units of the issuer held by the reporting person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.